Lhasa Limited shared knowledge shared progress
Publications
  • Highlighted Item:
  • Publisher:
    Reproductive Toxicology
  • Publication Date:
    FEB 2020
  • Reference:
    Reproductive Toxicology (2020), Volume 93, April 2020, Pages 199-210
  • DOI:
    https://doi.org/10.1016/j.reprotox.2020.02.011
  • PMID:
  • Publication Type:
    Paper
  • Related Products:
  • Scientific Area:
  • Endpoint:
    Reprotox
  • Industry Type:
  • Related event:

Predicting the safety of medicines in pregnancy: A workshop report

Clements JM; Hawkes RG; Jones D; Adjei A; Chambers T; Simon L; Fowkes A; Prior H; Sewell F; Stemplewski H; Berry N; Price S; Pirmohamed M; Piersma H; Waxenecker G; Barrow P; Beekhuijzen MEW;

In 2017, a UK Commission on Human Medicines (CHM) Expert Working Group [6] produced a set of recommendations aimed at improving the evidence base for medicines taken during pregnancy and lactation. One such recommendation was the delivery of a workshop to consider how non clinical data could be made more predictable and accessible, as well as the feasibility of using computer modelling and molecular structural alerts to generate safety signals from in vivo and in vitro data. This workshop was held in January 2019. The MHRA then organised the workshop bringing together experts from different backgrounds (academia, regulators, industry, CROs, software vendors) to discuss the status of the current developmental toxicity testing paradigm and the challenges and opportunities presented when considering novel approaches for the purpose of improving the predictability of non clinical data.

Visit site

© 2020 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Thanks to QuestionPro's generosity, we now have survey software that powers our data intelligence.